A spotlight on the Pharmalys Regulatory Affairs Unit

Jul 15, 2025 | Quality & Business Excellence

As clinical research expands rapidly across the African continent, the demand for strategic and locally grounded regulatory support is becoming more critical than ever. From clinical trial start-up to post-marketing activities, effective regulatory oversight is key to ensuring timely access to safe, effective, and high-quality health products. Recognising and anticipating this evolution, Pharmalys pays tribute to its dedicated Regulatory Affairs and Study Start-up Unit (RAS Unit), a team committed to supporting research and development with precision, regional expertise, and unwavering integrity.

In an increasingly complex regulatory environment shaped by evolving ethical standards, scientific advancements, and national requirements, the Pharmalys RAS Unit plays a pivotal role. The team supports the successful launch and conduct of clinical trials, ensures compliance across all phases of the healthcare product lifecycle, and helps safeguard the rights and well-being of research participants, all while enabling sponsors and partners to navigate Africa’s diverse regulatory landscapes with confidence.

Regulatory Affairs Management at Pharmalys

Combining deep scientific expertise with a comprehensive understanding of local, regional, and international regulatory frameworks, the RAS Unit supports every stage of the clinical development process. From early phase trials through to post-marketing surveillance, the team works with precision, responsiveness, and regional insight to deliver robust regulatory solutions tailored to each project’s unique needs.

Key services include:

  • Developing regulatory strategies tailored to local and global requirements
  • Managing overall regulatory activities and projects
  • Preparing and submitting Clinical Trial Applications (CTAs)
  • Liaising with Ethics Committees and National Regulatory Authorities
  • Reviewing Informed Consent Forms and Protocols for compliance
  • Ensuring continuous regulatory compliance throughout project life cycles
  • Preparing amendments, reports, and ensuring inspection readiness
  • Mapping regulatory intelligence and requirements
  • Supporting the establishment of local insurance
  • Managing import licensing procedures
  • Translating and/or supporting translation of regulatory documentation
  • Delivering training and capacity-building initiatives for regulatory compliance

Why Their Work Matters

In clinical research, time and trust are everything. A well-executed regulatory strategy minimises delays, preserves data integrity, and builds confidence among regulatory bodies, sponsors, investigators, and participants.

At Pharmalys, we combine our extensive local knowledge with international standards to help our partners navigate regulatory complexity across Africa with clarity and confidence.

Want to learn more or work with our team?

Contact us at regulatory@pharmalys.com to explore how we can support your project.

16 Days of Activism 2025: A Call to End Gender-Based Violence

16 Days of Activism 2025: A Call to End Gender-Based Violence

From 25 November to 10 December each year, the global community highlights the 16 Days of Activism Against Gender-Based Violence – a period dedicated to raising awareness, driving action and engaging all sectors of society to prevent and respond to violence rooted in...

Celebrating a Milestone in GCLP Compliance!

Celebrating a Milestone in GCLP Compliance!

We are thrilled to announce the successful completion of the initial GCLP accreditation audit at Hararghe Health Research Laboratory, Haramaya University College of Health and Medical Sciences, Harar, Ethiopia. The audit took place on 16–17 October 2025 and marked a...

Movember 2025: Raising Awareness for Men’s Health

Movember 2025: Raising Awareness for Men’s Health

November often signals the start of the festive season in many places, but for men’s health it holds a special significance: Movember. This annual campaign invites men (and those who support them) to pause, reflect and act on several critical health issues that too...

Highlights from the final Pharmalys Voice Meeting of 2025

Highlights from the final Pharmalys Voice Meeting of 2025

On September 25, 2025, Pharmalys held its third and final Pharmalys Voice meeting of the year, bringing together colleagues from across the company in a fun and interactive virtual gathering. The meeting involved presentations from colleagues, engaging discussions,...

Ethiopia Reaches WHO Maturity Level 3

Ethiopia Reaches WHO Maturity Level 3

On 3 October 2025, Dr Mekdes Daba, Health Minister of Ethiopia, announced a major achievement for the country: the formal recognition of the Ethiopian Food and Drug Authority (EFDA) as a Maturity Level 3 (ML3) regulatory system by the World Health Organization (WHO)....